The high pancreas uptake limits the application of these GRPR-targeting radiopharmaceuticals for detecting cancer lesions adjacent to or located in the pancreas and lowers the maximum tolerated dose for targeted radioligand therapy to minimize toxicity. The gene discussed is GRPR; the disease is cancer.